Obagi Medical Partners with ProMD Health for Real-World Evidence Study on saypha® MagIQ™
Event summary
- Obagi Medical, part of Waldencast plc, collaborates with ProMD Health under the ALOHA Program to evaluate saypha® MagIQ™ across 17 practice locations.
- ProMD was selected for its multi-location network and commitment to clinical excellence.
- The program combines real-world evaluation with integrated skincare protocols to assess clinical efficacy and patient experience.
- saypha® MagIQ™ utilizes MACRO Core Technology for stable hyaluronic acid matrix delivery.
The big picture
This collaboration underscores a growing trend in the aesthetics industry toward real-world evidence as a key differentiator. By partnering with ProMD Health, Obagi Medical aims to bolster saypha® MagIQ™’s clinical credibility, aligning with Waldencast’s strategy of scaling high-growth brands through data-driven innovation. The move also highlights the importance of multi-location practice networks in validating new aesthetic technologies.
What we're watching
- Clinical Validation
- How the real-world evidence from ProMD’s evaluation will impact saypha® MagIQ™’s market adoption and differentiation.
- Scalability
- Whether Obagi Medical can replicate this partnership model with other multi-location practices to accelerate product launches.
- Competitive Positioning
- The pace at which Waldencast can leverage Obagi’s evidence-based approach to strengthen its portfolio in the competitive aesthetics market.